Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
Pliant ends lung disease program over rise in adverse events
Pliant has terminated its IPF program after digging into the increased rate of adverse events from a 2b/3 trial of its lead candidate bexotegrast.
James Waldron
Jun 30, 2025 4:49am
Transpire licenses PDE4 inhibitor for lung disease
Jun 3, 2025 9:45am
PureTech's deupirfenidone shows durable effect in IPF study
May 20, 2025 5:15pm
Boehringer's phase 3 lung data get muted response from analysts
May 19, 2025 9:24am
Pliant terminates lung disease trial due to adverse events
Mar 3, 2025 11:30am
Boehringer widens fibrosis drug's potential after 2nd ph. 3 win
Feb 10, 2025 10:42am
